Exosome therapy vs GHK-Cu
Two regenerative pitches for skin and hair: a copper peptide with real biology in a dish, and a clinic procedure the FDA has issued safety reports about.
Short answer
Exosome therapy and GHK-Cu are both graded preclinical / minimal, which leaves little or no controlled human data to choose between them. What does differ is access, since exosome therapy is legitimately available only inside clinical trials, while GHK-Cu is sold in cosmetic skin-care products.
Exosome therapy
Extracellular vesicles, EV therapy
No FDA-approved exosome product exists for any indication, and the agency reports blindness, tumor formation and infections from unapproved ones. Legitimate first-in-human work is under way; none of it supports what clinics sell.
Full Exosome therapy evidence reviewGHK-Cu
Copper tripeptide
Real tissue-remodeling biology, mostly in-vitro and topical; a cosmetic signal, not systemic anti-aging proof.
Full GHK-Cu evidence reviewExosome therapy vs GHK-Cu: head to head
- FDA status / approved use
Exosome therapy
No FDA-approved exosome products; human use allowed only under an Investigational New Drug applicationGHK-Cu
Long-established cosmetic ingredient in skincare creams and serums- Marketed for
Exosome therapy
Hair regrowth, skin rejuvenation, joint repair, general regenerative claimsGHK-Cu
Skin, hair, 'anti-aging'- Outcome areas
Exosome therapy
Skin / hair; Injury recovery / tissue repair; Joint / bone healthGHK-Cu
Skin / hair; Longevity / lifespan- Evidence grade
Exosome therapy
Preclinical / minimalGHK-Cu
Preclinical / minimal- How it works
Exosome therapy
Small vesicles that cells release to carry proteins, lipids and RNA between cellsGHK-Cu
Copper-binding tripeptide that stimulates collagen synthesis in lab studies- Route and dosing
Exosome therapy
Injection, typically given in clinicsGHK-Cu
Topical cream or serum; injected forms are also sold- Headline human result
Exosome therapy
Not establishedGHK-Cu
Not established- Strongest evidence
Exosome therapy
Systematic review & meta-analysis of EV trials, J Extracell Vesicles 2024. Little or no controlled human outcome data for the marketed useExosome therapy evidence reviewPubMed 38958077GHK-Cu
J Biomater Sci, 2008. Little or no controlled human outcome data for the marketed useGHK-Cu evidence reviewPubMed 18644225- Key safety signal
Exosome therapy
FDA has reports of blindness, tumor formation and infections after unapproved products including exosomesGHK-Cu
Injected form has no established dosing or long-term safety data; copper can be toxic in excess- How it is obtained
Exosome therapy
Legitimately available only inside clinical trialsGHK-Cu
Sold in cosmetic skin-care products
| Exosome therapy | GHK-Cu | |
|---|---|---|
| FDA status / approved use | No FDA-approved exosome products; human use allowed only under an Investigational New Drug application | Long-established cosmetic ingredient in skincare creams and serums |
| Marketed for | Hair regrowth, skin rejuvenation, joint repair, general regenerative claims | Skin, hair, 'anti-aging' |
| Outcome areas | Skin / hair; Injury recovery / tissue repair; Joint / bone health | Skin / hair; Longevity / lifespan |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| How it works | Small vesicles that cells release to carry proteins, lipids and RNA between cells | Copper-binding tripeptide that stimulates collagen synthesis in lab studies |
| Route and dosing | Injection, typically given in clinics | Topical cream or serum; injected forms are also sold |
| Headline human result | Not established | Not established |
| Strongest evidence | Systematic review & meta-analysis of EV trials, J Extracell Vesicles 2024. Little or no controlled human outcome data for the marketed useExosome therapy evidence reviewPubMed 38958077 | J Biomater Sci, 2008. Little or no controlled human outcome data for the marketed useGHK-Cu evidence reviewPubMed 18644225 |
| Key safety signal | FDA has reports of blindness, tumor formation and infections after unapproved products including exosomes | Injected form has no established dosing or long-term safety data; copper can be toxic in excess |
| How it is obtained | Legitimately available only inside clinical trials | Sold in cosmetic skin-care products |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
Neither supports the rejuvenation claims made for it, but the risk is not symmetrical. GHK-Cu has genuine tissue-remodeling biology that is mostly in-vitro and topical — a cosmetic signal, not systemic anti-aging proof. Exosome therapy has no FDA-approved product for any indication, and the agency has reported blindness, tumor formation and infections tied to unapproved ones; legitimate first-in-human work is under way, and none of it supports what clinics currently sell. A topical with thin evidence and an injected procedure with safety reports behind it are not the same kind of bet.
Exosome therapy fits if
You are tracking the legitimate first-in-human extracellular-vesicle research rather than buying a clinic procedure today.
GHK-Cu fits if
You want the topical, cosmetic end of this claim and read the evidence as a skin signal rather than anti-aging.
Exosome therapy vs GHK-Cu: common questions
- Is either exosome therapy or GHK-Cu FDA-approved?
- No. For exosome therapy, there are no FDA-approved exosome products; human use allowed only under an Investigational New Drug application. GHK-Cu is a long-established cosmetic ingredient in skincare creams and serums.
- Which has stronger human evidence, exosome therapy or GHK-Cu?
- Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for exosome therapy is Systematic review & meta-analysis of EV trials, J Extracell Vesicles 2024; for GHK-Cu, it is J Biomater Sci, 2008.
- What are the main safety concerns with exosome therapy and GHK-Cu?
- With exosome therapy, FDA has reports of blindness, tumor formation and infections after unapproved products including exosomes. With GHK-Cu, injected form has no established dosing or long-term safety data; copper can be toxic in excess.
Key studies behind each
Exosome therapy
- Johnson J, Law SQK, Shojaee M, Hall AS, et al. (2023). First-in-human clinical trial of allogeneic, platelet-derived extracellular vesicles as a potential therapeutic for delayed wound healing. J Extracell Vesicles. PubMed 37353884
- Van Delen M, Derdelinckx J, Wouters K, Nelissen I, et al. (2024). A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J Extracell Vesicles. PubMed 38958077
- Queen D, Avram MR. (2025). Exosomes for Treating Hair Loss: A Review of Clinical Studies. Dermatol Surg. PubMed 39447204
- Lee KWA, Chan LKW, Hung LC, Phoebe LKW, et al. (2024). Clinical Applications of Exosomes: A Critical Review. Int J Mol Sci. PubMed 39063033
GHK-Cu
- Pickart L. (2008). The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. PubMed 18644225
- Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. PubMed 26236730
- Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. PubMed 29986520
- Dou Y, Lee A, Zhu L, et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. PubMed 35083444
The full evidence reviews
- Exosome therapy: what the evidence and the FDA actually say
There are no FDA-approved exosome products, and the agency has logged reports of blindness, tumor formation and infections from unapproved ones — while clinics sell them for hair, skin and joints. A straight read.
Updated August 2026
- GHK-Cu: the copper peptide between real skincare and overclaim
A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm GHK-Cu availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Live VitalCalifornia Trim ClinicDr. Gillis' Wellness CenterElitePhysiqMDEmbraceRXEvolve Telemed